Sino Biological Launches XPressMAX™ Cell-Free Protein Synthesis Kit to Accelerate AI-Driven Antibody Discovery
Sino Biological's new XPressMAX™ Cell-Free Protein Synthesis Kit enables ultra-fast protein synthesis in three hours, supporting AI-powered high-throughput antibody drug discovery by eliminating traditional cell-based constraints.
Sino Biological, Inc. (Shenzhen Stock Exchange: 301047.SZ), a global leader in recombinant technology, has announced the launch of its XPressMAX™ Cell-Free Protein Synthesis Kit (Cat#: CFKIT02). This innovative product is designed to accelerate artificial intelligence (AI)-driven high-throughput screening pipelines for antibody drug discovery. By enabling rapid, efficient in vitro production of target proteins and antibodies, the kit eliminates the constraints of traditional cell-based expression systems, potentially reducing development timelines and costs significantly.
The XPressMAX™ kit leverages advanced cell-free protein synthesis technology based on an E. coli lysate, fully supplemented with essential transcription and translation components. It allows direct protein synthesis from plasmid or PCR templates, making it particularly suitable for antibody drug discovery. The kit supports rapid expression and validation of VHH, scFv, Fab, and miniproteins, which are critical for AI-driven screening platforms that demand speed and throughput. Sino Biological has already established a high-throughput cell-free expression platform that validates over 2,000 scFv/VHH molecules in just 3-4 weeks, matching the rapid iteration of AI algorithms.
Key highlights of the XPressMAX™ kit include ultra-fast synthesis completed in just three hours, a success rate greater than 99%, and support for complex disulfide bonding, enabling native folding and bioactivity without additional enhancers. According to Dr. Rob Burgess, Chief Business Officer at Sino Biological US, Inc., “Our XPressMAX™ is a significant advancement in research tools and reagents for next-generation therapeutic discovery. By combining rapid, reliable protein expression with intelligent screening, we are helping our partners compress antibody discovery timelines without compromising quality.” Dr. Jie Zhang, Sino Biological’s General Manager, added, “AI is revolutionizing antibody screening, but it demands expression systems that can match its speed and throughput. XPressMAX™ achieves rapid, high-success expression of challenging proteins in as little as 3 hours.”
The implications of this launch are significant for the pharmaceutical and biotechnology industries. As AI continues to transform drug discovery, the bottleneck often shifts to the experimental validation of computational predictions. Traditional cell-based protein expression can take days or weeks, hindering the iterative cycle of AI-driven design. XPressMAX™ addresses this gap by providing a rapid, reliable, and high-throughput solution that can keep pace with AI algorithms. This could lead to faster identification of promising antibody candidates, reduced costs in early-stage research, and ultimately, accelerated development of new therapies for diseases such as cancer, autoimmune disorders, and infectious diseases.
Researchers can visit www.sinobiological.com to explore more about XPressMAX™ or request a free sample. Sino Biological, headquartered in Houston, Texas, with operations in Canada, serves researchers in over 90 countries, maintaining a stringent quality management system across all products.